文献速递心境障碍精神分裂症与精神病性障碍

边缘型人格障碍药物治疗疗效与安全性的系统综述与网状Meta分析

Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis.
PubMed 文献 · Mol Psychiatry · 2026-02-10

结果显示托吡酯、拉莫三嗪和阿立哌唑对敌意、攻击性和愤怒的改善最有效,而阿普唑仑、哌甲酯、氟哌啶醇和丙戊酸盐证据确定性低,不应优先使用。

要点

  • 托吡酯(200-250 mg/日,8-10周)、拉莫三嗪(50-200 mg/日,8周)和阿立哌唑(15 mg/日,8周)最有效改善敌意、攻击性和愤怒控制。
  • 卡马西平(200-1200 mg/日,6周)改善冲动性,阿森那平(5-10 mg/日,12周)改善情绪失调,但证据确定性分别为低和极低。
  • 阿普唑仑、哌甲酯、氟哌啶醇和丙戊酸盐在未选择的BPD样本中仅低确定性证据,不应优先使用。

核心结论

  • 托吡酯、拉莫三嗪和阿立哌唑对BPD的敌意、攻击性和愤怒控制有较好疗效且证据确定性为高至中等。
  • 卡马西平和阿森那平分别改善冲动性和情绪失调,但证据确定性低至极低。
  • 阿普唑仑、哌甲酯、氟哌啶醇和丙戊酸盐证据确定性低,不应作为优先选择。

研究设计与样本

  • 系统检索Medline、Web of Science和Google Scholar(2024年1月15日至2月12日)纳入比较活性药物与安慰剂或其他药物的随机临床试验。
  • 采用随机效应配对和网状Meta分析估计标准化均数差,并使用GRADE NMA指南评定显著药物-安慰剂比较的证据等级。

主要发现

  • 托吡酯(200-250 mg/日,8-10周)、拉莫三嗪(50-200 mg/日,8周)和阿立哌唑(15 mg/日,8周)最有效减少敌意、攻击性和愤怒并改善愤怒控制。
  • 卡马西平(200-1200 mg/日,6周)改善冲动性,阿森那平(5-10 mg/日,12周)改善情绪失调。
  • 托吡酯、拉莫三嗪和阿立哌唑对敌意和愤怒减少的证据等级分别为高、中等和中等;卡马西平和阿森那平对冲动性和情绪失调的证据等级分别为低和极低。

关键数值与推荐

  • 托吡酯200-250 mg/日持续8-10周对敌意和愤怒减少的证据等级为高。
  • 拉莫三嗪50-200 mg/日持续8周对敌意和愤怒减少的证据等级为中等。
  • 阿立哌唑15 mg/日持续8周对敌意和愤怒减少的证据等级为中等。
  • 卡马西平200-1200 mg/日持续6周对冲动性改善的证据等级为低。
  • 阿森那平5-10 mg/日持续12周对情绪失调改善的证据等级为极低。

临床怎么用

  • 处方应限于特定个体化适应症,如惊恐、共病ADHD或短暂精神病性特征,并需谨慎临床评估。
  • 托吡酯、拉莫三嗪和阿立哌唑可考虑用于BPD的敌意、攻击性和愤怒控制。
  • 阿普唑仑、哌甲酯、氟哌啶醇和丙戊酸盐不应在未选择的BPD样本中优先使用。

局限性

  • 部分药物-安慰剂比较的证据确定性低或极低,限制结论可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with borderline personality disorder (BPD) are over-represented in psychiatric services, and their suicide mortality is markedly higher than that of the general population. This network meta-analysis evaluated and compared the efficacy and safety of pharmacological treatments for symptoms of BPD. A systematic search of Medline®, Web of Science®, and Google Scholar® identified randomised clinical trials comparing active drugs with placebo or another agent between 15 January and 12 February 2024. Standardised mean differences were estimated using random-effects pairwise and network meta-analyses. The level of evidence (LoE) for significant drug-placebo comparisons was rated using GRADE NMA guidance. Thirty-five trials including 2551 participants assessed 26 treatments against placebo: 18 had low, five moderate, and 12 high risk of bias. Topiramate (200-250 mg/day, 8-10 weeks), lamotrigine (50-200 mg/day, 8 weeks), and aripiprazole (15 mg/day, 8 weeks) most effectively reduced hostility, aggressiveness, and anger, and improved anger control. Carbamazepine (200-1200 mg/ day, 6 weeks) and asenapine (5-10 mg/day, 12 weeks) improved impulsivity and emotional dysregulation, respectively. Topiramate, lamotrigine, and aripiprazole demonstrated high, moderate, and moderate LoE for hostility and anger reduction. Carbamazepine and asenapine demonstrated low and very low LoE for impulsivity and emotional dysregulation. Conversely, alprazolam, methylphenidate, haloperidol, and valproate had only low-certainty evidence in unselected BPD samples and should not be prioritised. Prescription should be limited to specific, individualised indications, such as panic, comorbid ADHD, or transient psychotic features, following cautious clinical appraisal.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gerolymos C, Garosi A, Boyer L, et al. Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis. Mol Psychiatry. 2026. PMID: 41667836. doi:10.1038/s41380-026-03451-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。